TY - JOUR
T1 - Clonal expansion and myeloid leukemia progression modeled by multiplex gene editing of murine hematopoietic progenitor cells
AU - Shi, Xiangguo
AU - Kitano, Ayumi
AU - Jiang, Yajian
AU - Luu, Victor
AU - Hoegenauer, Kevin A.
AU - Nakada, Daisuke
N1 - Publisher Copyright:
© 2018 ISEH – Society for Hematology and Stem Cells
PY - 2018/8
Y1 - 2018/8
N2 - Recent advances in next-generation sequencing have identified novel mutations and revealed complex genetic architectures in human hematological malignancies. Moving forward, new methods to quickly generate animal models that recapitulate the complex genetics of human hematological disorders are needed to transform the genetic information to new therapies. Here, we used a ribonucleoprotein-based CRISPR/Cas9 system to model human clonal hematopoiesis of indeterminate potential and acute myeloid leukemia (AML). We edited multiple genes recurrently mutated in hematological disorders, including those encoding epigenetic regulators, transcriptional regulators, and signaling components in murine hematopoietic stem/progenitor cells. Tracking the clonal dynamics by sequencing the indels induced by CRISPR/Cas9 revealed clonal expansion in some recipient mice that progressed to AML initiated by leukemia-initiating cells. Our results establish that the CRISPR/Cas9-mediated multiplex mutagenesis can be used to engineer a variety of murine models of hematological malignancies with complex genetic architectures seen in human disease.
AB - Recent advances in next-generation sequencing have identified novel mutations and revealed complex genetic architectures in human hematological malignancies. Moving forward, new methods to quickly generate animal models that recapitulate the complex genetics of human hematological disorders are needed to transform the genetic information to new therapies. Here, we used a ribonucleoprotein-based CRISPR/Cas9 system to model human clonal hematopoiesis of indeterminate potential and acute myeloid leukemia (AML). We edited multiple genes recurrently mutated in hematological disorders, including those encoding epigenetic regulators, transcriptional regulators, and signaling components in murine hematopoietic stem/progenitor cells. Tracking the clonal dynamics by sequencing the indels induced by CRISPR/Cas9 revealed clonal expansion in some recipient mice that progressed to AML initiated by leukemia-initiating cells. Our results establish that the CRISPR/Cas9-mediated multiplex mutagenesis can be used to engineer a variety of murine models of hematological malignancies with complex genetic architectures seen in human disease.
UR - http://www.scopus.com/inward/record.url?scp=85047793531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047793531&partnerID=8YFLogxK
U2 - 10.1016/j.exphem.2018.04.009
DO - 10.1016/j.exphem.2018.04.009
M3 - Article
C2 - 29751067
AN - SCOPUS:85047793531
SN - 0301-472X
VL - 64
SP - 33-44.e5
JO - Experimental Hematology
JF - Experimental Hematology
ER -